Zepbound Alternatives (2026): Wegovy, Foundayo, Compounded Tirzepatide & The Caremark Formulary Reality

This Zepbound-alternatives guide is part of Weight Loss Rankings' living editorial database — 1,140+ research articles and 640+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

Most patients searching “Zepbound alternative” in 2026 are not looking for a better drug. Zepbound (tirzepatide, Eli Lilly) is the highest-effect FDA-approved anti-obesity medication on the US market — -20.9% mean body-weight loss at the 15 mg maintenance dose over 72 weeks in the SURMOUNT-1 phase 3 trial^[1], and SURMOUNT-5^[2] (NEJM 2025) reaffirmed tirzepatide's superiority over semaglutide head-to-head. Patients searching this query are typically formulary-displaced, denial-displaced, or cost-displaced. The dominant trigger has been the CVS Caremark July 2025 formulary swap that removed Zepbound from most commercial formularies in favor of Wegovy as the single preferred GLP-1 for weight management. Caremark added Zepbound back as an additional preferred option on October 1, 2026^[7], so for many Caremark members the first step is now to check whether their plan covers Zepbound again. Below: the realistic alternatives in rank order, the cross-trial efficacy with explicit caveats, the cash-pay paths, the insurance appeal playbook to get Zepbound back, and the patient-profile guidance.

Why patients are looking for Zepbound alternatives in 2026

Across patient queries and the published payer-policy record, three precipitating events drive the  “Zepbound alternative” search:

1. The CVS Caremark July 2025 formulary swap. CVS Caremark — Aetna's PBM and a CVS Health subsidiary — removed Zepbound from most commercial formularies effective July 2025 in favor of Wegovy as the single preferred GLP-1 for chronic weight management. This formulary edit overrode existing Aetna and CVS commercial medical-policy bulletins at point-of-sale on the affected formulary codes (ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC). Patients previously stable on Zepbound were forced to switch to Wegovy or pay cash. On October 1, 2026, Caremark added Zepbound back to its commercial formularies as an additional preferred option^[7]; if your plan adopted the change and covers weight-loss drugs, you may not need an alternative at all. Detailed step-by-step appeal language is in our insurance dropped GLP-1 coverage appeal playbook.
2. BMI clawback / continuation denials. Many commercial plans renew Zepbound coverage only if the patient maintains a continuation BMI threshold or documented body-weight loss against a stop-rule (typically 5%, or 4% on Aetna 1227-C for Saxenda). Patients who plateaued under the threshold can lose coverage at renewal even after a successful initial PA. See Aetna GLP-1 PA guide and Cigna GLP-1 PA guide for the verbatim continuation language.
3. Cost. Zepbound LillyDirect Self Pay runs $299-$449/month (vials) or $299-$699/month (KwikPen) in 2026. Without insurance, multi-year therapy is a $4,000-$8,000 annual line item. Wegovy NovoCare at $199/month for a new patient's first two months (0.25/0.5 mg), then $349/month, is the cheapest brand-name injectable cash-pay start; Foundayo at $149/month is the cheapest brand-name FDA-approved option overall.

The realistic alternatives, in rank order

• 1. Wegovy — different molecule (semaglutide 2.4 mg), lower effect size (-14.9% at 68 weeks vs Zepbound's -20.9% at 72 weeks in cross-trial comparison), but Caremark-preferred since July 2025 (alongside Zepbound since October 1, 2026) and the path of least resistance on plans that still exclude Zepbound.
• 2. Mounjaro — the SAME tirzepatide molecule but indicated only for type 2 diabetes per its Section 1 label. Generally not covered without a T2D diagnosis.
• 3. Foundayo — oral GLP-1 receptor agonist (orforglipron, FDA-approved April 2026), -11.1% at the 17.2 mg labeled maximum in adults without T2D per the Section 14 prescribing information, $149/month cash-pay, $25/month with the Lilly Savings Card for commercially insured patients.
• 4. Compounded tirzepatide — cash-pay $200-$300/month range in the 2026 telehealth market. The FDA enforcement-discretion period for tirzepatide compounding ENDED October 2024. Continued 503A activity is regulatory gray-zone.
• 5. Zepbound itself via cash-pay channels — LillyDirect Self Pay vials $299-$449, Sam's Club Plus KwikPen $299-$699, GoodRx-listed retail pricing. Sometimes cheaper than the alternatives anyway depending on dose.

Cross-trial efficacy comparisons in this article are indirect — different populations, different durations, different primary endpoints. The only direct head-to-head between any two of these drugs is SURMOUNT-5^[2] (tirzepatide vs semaglutide in chronic weight management). SURPASS-2 (PMID 34170647) is the head-to-head in T2D, not obesity. Wegovy is not equivalent to Zepbound — it is a different molecule with a meaningfully smaller mean body-weight effect across the published trial record.

The first-line alternative: Wegovy (semaglutide 2.4 mg)

Wegovy^[3] is once-weekly subcutaneous semaglutide 2.4 mg, sponsored by Novo Nordisk, FDA-approved for chronic weight management since June 2021. It is structurally and chemically distinct from tirzepatide: semaglutide is a pure GLP-1 receptor agonist, while tirzepatide is a dual GIP + GLP-1 receptor agonist. The verbatim Section 14 STEP-1 efficacy from the FDA-approved prescribing information is -14.9% mean body-weight loss at 68 weeks on Wegovy 2.4 mg vs -2.4% on placebo (n=1,961, ITT). About 86% of Wegovy patients lost at least 5% of baseline body weight vs 31.5% on placebo.

Why Wegovy is the first-line alternative for displaced patients:

• Caremark-preferred since July 2025. Caremark commercial formularies cover Wegovy as a preferred option, with no prior authorization escalation required for patients who already met BMI/comorbidity criteria. Since October 1, 2026 Zepbound is a preferred option again too, so Wegovy is the default mainly where a plan still excludes Zepbound.
• Same FDA chronic-weight-management indication. Wegovy and Zepbound share the Section 1 indication: adults with obesity, or adults with overweight plus at least one weight-related comorbid condition. The labels print no BMI numbers; their pivotal trials (STEP 1, SURMOUNT-1) enrolled BMI at least 30, or at least 27 with a weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, OSA, or cardiovascular disease).
• Labeled cardiovascular benefit Zepbound does NOT have. The SELECT trial (PMID 37952131) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by ~20% in patients with established CVD and obesity but without diabetes. Wegovy carries an FDA-labeled indication for CV risk reduction in this population. Zepbound does not yet carry an analogous label.

The trade-off — and this is the honest framing:

• Lower expected weight loss. -14.9% mean on Wegovy STEP-1 vs -20.9% mean on Zepbound SURMOUNT-1 in cross-trial indirect comparison. SURMOUNT-5^[2], the only direct head-to-head, found tirzepatide superior. Patients who lost 18-25% of body weight on Zepbound should expect a smaller maintenance loss on Wegovy.
• Different molecule, different titration. Wegovy escalates 0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg with at least 4 weeks between increases. Patients restarting Wegovy from prior Zepbound therapy typically begin at the lowest 0.25 mg starter dose; there is no FDA-published dose-equivalence conversion table.
• Side-effect profile is broadly similar but not identical. See the detailed cross-drug comparison in our Zepbound vs Wegovy side-effects comparison.

For the molecule-vs-molecule context, see Wegovy vs Mounjaro: different molecules. For the dose-by-dose switching guide: Wegovy and Zepbound switch dose-equivalence guide.

What about Mounjaro?

Mounjaro is the SAME tirzepatide molecule as Zepbound — same active ingredient, same manufacturer (Eli Lilly), same once-weekly subcutaneous injection, same dose strengths (2.5/5/7.5/10/12.5/15 mg). The DailyMed Section 1 indication is the only thing that differs:

• Mounjaro Section 1: indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus [and] to reduce the risk of major adverse cardiovascular (CV) events … in adults with type 2 diabetes mellitus who are at high risk for these events. Type 2 diabetes ONLY. The Mounjaro DailyMed label does NOT contain a chronic weight management indication.
• Zepbound Section 1: chronic weight management (Section 1.1) PLUS obstructive sleep apnea (Section 1.2). No T2D indication.

For patients with type 2 diabetes plus obesity, Mounjaro is a covered path that also produces meaningful weight loss. For patients without type 2 diabetes, the Mounjaro coverage path is generally closed: commercial PA criteria across Aetna, Cigna, BCBS, and UnitedHealthcare require a documented T2D diagnosis (HbA1c at least 6.5% or physician-attested T2D) to approve Mounjaro. Off-label Mounjaro for weight loss without diabetes is not a practical insurance path. For the verbatim molecule-and-indication framing, see diabetes-vs-weight-loss GLP-1 disambiguation and Mounjaro vs Zepbound FDA prescribing information explained. If you are looking for a prescriber, our guide to getting Mounjaro online walks through the telehealth steps.

What about Foundayo?

Foundayo (orforglipron) is the first small-molecule (non-peptide) oral GLP-1 receptor agonist FDA-approved for chronic weight management — approved April 1, 2026, sponsored by Eli Lilly. Unlike semaglutide and tirzepatide, which are peptide drugs that must be injected to survive stomach acid, orforglipron is a non-peptide small molecule that survives oral administration. Per the Section 14 FDA-approved prescribing information and the ATTAIN-1 phase 3 trial^[4], the labeled-dose efficacy is -11.1% mean body-weight loss (about 25 lb from a 103 kg baseline) at the labeled maximum dose of 17.2 mg in adults without type 2 diabetes at 72 weeks.

Important caveat on the Foundayo numbers. ATTAIN-1^[4] reports its orforglipron arms as 6, 12, and 36 mg of an investigational formulation, which the FDA label presents as the marketed 5.5, 9, and 17.2 mg tablets. The 36 mg trial arm is the 17.2 mg tablet, not a higher dose, and no 36 mg tablet is sold. The paper reports -12.4% on the efficacy estimand and -11.2% on the treatment-regimen estimand for that arm; the label reports -11.1%.

Foundayo's case for Zepbound-displaced patients:

• Cheapest brand-name FDA-approved option. $149/month cash-pay list price; $25/month with the Lilly Savings Card for commercially insured patients.
• Daily oral pill, no injections. No needle disposal, no refrigeration, no cold chain. Foundayo can be taken any time of day, with or without food, with no water restrictions per the Section 2 dosing instructions.
• Shorter half-life. Orforglipron half-life 29-49 hours per Section 12.3 vs tirzepatide half-life ~5 days. Useful for pre-procedure hold and pre-pregnancy planning.

The honest trade-offs:

• Roughly half the expected weight loss. -11.1% labeled-dose Foundayo vs -20.9% Zepbound 15 mg in cross-trial indirect comparison. Patients who responded strongly to Zepbound should expect a substantively smaller loss on Foundayo.
• Slower titration. Foundayo Section 2 requires at least 30 days between dose increases across 6 dose steps (0.8 to 2.5 to 5.5 to 9 to 14.5 to 17.2 mg). Total time to maintenance ~6 months.
• Drug-drug interaction caveat. Foundayo Section 7 caps the maximum dose at 9 mg/day with strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir-boosted antivirals). Zepbound has no analogous DDI cap. Foundayo Section 7 also recommends a non-oral contraceptive method for 30 days after starting and 30 days after each dose increase — a label asymmetry unique to Foundayo among the three.
• No OSA indication. Foundayo is not labeled for obstructive sleep apnea.

For the dose-by-dose switching guide between these molecules, see Foundayo and Zepbound switch dose-equivalence guide. For the three-way head-to-head: Foundayo vs Wegovy vs Zepbound comparison. For the dosing protocol: how to take Foundayo.

Compounded tirzepatide as cash-pay alternative

Compounded tirzepatide — tirzepatide produced in a 503A compounding pharmacy under a patient-specific prescription rather than mass-manufactured by Eli Lilly under NDA 217806 — was the dominant cash-pay path for tirzepatide therapy in 2023 and 2024 while Zepbound was on the FDA Drug Shortage List. Cash-pay pricing in the 2026 telehealth market typically runs $200-$300/month for compounded tirzepatide multi-vial dispensing, before the provider visit fee. Our guide to getting tirzepatide online explains how these prescriptions work.

Generic tirzepatide does NOT exist as of May 2026. Eli Lilly's composition-of-matter patent on tirzepatide runs into the 2030s; any product marketed as “generic tirzepatide” from a non-Lilly source is misbranding under the Federal Food, Drug, and Cosmetic Act. The earliest plausible generic timeline is documented in our Zepbound generic / biosimilar timeline.

What about Zepbound through cash-pay channels?

Patients who ASSUME Zepbound is unaffordable without insurance are sometimes wrong. The 2026 cash-pay landscape for brand Zepbound:

• LillyDirect Self Pay vials: $299/month (2.5 mg starter), $399/month (5 mg), $449/month (7.5/10/12.5/15 mg). Single-use vials with separate syringe. Prices as of May 2026.
• Sam's Club Plus KwikPen: $299 (2.5 mg) / $399 (5 mg) / $499 (7.5 mg) / $699 (10/12.5/15 mg) per 4-pen box. Free same-day refrigerated delivery for Plus members.
• GoodRx-listed retail pharmacy pricing: variable by ZIP and pharmacy. See GLP-1 GoodRx cash-pay coupon channel guide for the framework.
• Lilly Savings Card (commercially insured patients only, not Medicare/Medicaid) can reduce copay to as little as $25/month if Zepbound is on formulary.

At the 2.5-5 mg starter doses, Zepbound LillyDirect Self Pay ($299-$399) can be cheaper than compounded tirzepatide with provider visit fees ($200-$300 + $50-$100 visit) and cheaper than or equal to NovoCare Wegovy at its standard $349/month rate. Wegovy's $199/month NovoCare intro (a new patient's first two fills at 0.25/0.5 mg) is the only cash-pay path that beats Zepbound on price — at the cost of switching to a different molecule with lower mean efficacy.

Insurance appeal: getting Zepbound back

For patients whose plan still excludes Zepbound, the appeal pathway is real but high-effort. (On Caremark plans that adopted the October 1, 2026 change, start with a new standard Zepbound PA instead.) The condensed playbook:

1. Step 1 — Letter of Medical Necessity (LMN). Prescriber documents (a) the patient's response to Zepbound (% body weight loss, comorbidity improvement), (b) any documented intolerance or inadequate response to Wegovy if previously tried, and (c) the clinical reason a formulary swap to Wegovy is unsafe or inappropriate for this patient. The LMN is submitted to the PBM as a formulary exception request.
2. Step 2 — Tier exception / non-formulary override. If the LMN is denied, the prescriber files a non-formulary override appeal. The PBM has 72 hours (urgent) or 30 days (standard) to respond per ERISA and ACA appeal rules.
3. Step 3 — External Independent Review Organization (IRO) appeal. If the internal appeal is denied, the patient files an external appeal with an Independent Review Organization. IROs have ~45 day response windows. IRO decisions are binding on the plan.
4. Step 4 — HR / employer escalation for self-funded plans, or state insurance commissioner complaint for fully-insured plans.

The full step-by-step language, sample LMN templates, and the Caremark-specific formulary-code mapping are in our insurance dropped GLP-1 coverage appeal playbook.

For patients with OSA: Zepbound is the only FDA-approved option

Zepbound carries a Section 1.2 indication for moderate-to-severe obstructive sleep apnea in adults with obesity, granted on the basis of the SURMOUNT-OSA phase 3 trial^[5] which demonstrated tirzepatide reduced the apnea-hypopnea index (AHI) versus placebo over 52 weeks. The verbatim Section 1.2 language from the Zepbound DailyMed label^[6]:

ZEPBOUND is indicated as an adjunct to a reduced-calorie diet and increased physical activity for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Wegovy, Foundayo, Saxenda, Mounjaro, Qsymia, and Contrave are NOT FDA-approved for OSA. Patients whose Zepbound prescription was anchored on the OSA indication have no equivalent FDA-approved alternative as of May 2026. Off-label semaglutide for OSA is not a practical insurance path; the ongoing OASIS trial of semaglutide for OSA is investigational, not approved.

Picking your alternative based on displacement reason

If your displacement is the CVS Caremark July 2025 swap

• First move: check your plan's current formulary. CVS Caremark added Zepbound back as an additional preferred option on October 1, 2026, so if your plan adopted the change and covers weight-loss drugs, ask your prescriber to resubmit a Zepbound PA.
• If your plan still excludes Zepbound: switch to Wegovy via your existing PBM (path of least resistance).
• If Wegovy is intolerable at trial: file a Letter of Medical Necessity for Zepbound non-formulary exception with documented Wegovy adverse-event evidence.
• If you have established CVD: Wegovy may be CLINICALLY preferable anyway given the SELECT cardiovascular benefit.

If your displacement is BMI clawback / continuation denial

• First move: have your prescriber resubmit PA with documented body-weight loss and comorbidity improvement. Most plans grant continuation if you met the stop-rule.
• If continuation is denied: consider Foundayo at $25/month savings card or $149/month cash as a step-down maintenance option.

If your displacement is cost

• Cheapest path: Foundayo at $25/month (Savings Card) or $149/month (cash), oral pill.
• Cheapest brand-name injectable: Wegovy NovoCare at $199/month for a new patient's first two months, then $349/month.
• Don't rule out brand Zepbound: LillyDirect Self Pay $299-$449 vials may be cheaper than you think for the lower doses.

If your prescription was for OSA

• Zepbound is the ONLY FDA-approved option for OSA in 2026. Pursue the insurance appeal aggressively; cite the Section 1.2 indication and SURMOUNT-OSA^[5]. There is no equivalent alternative.

Bottom line

• Zepbound (tirzepatide 15 mg) at -20.9% mean weight loss in SURMOUNT-1^[1] remains the highest-effect FDA-approved AOM in 2026; SURMOUNT-5^[2] confirmed superiority over semaglutide head-to-head.
• The dominant 2026 reason patients search “Zepbound alternative” is the CVS Caremark July 2025 formulary swap, NOT a search for a better drug. Caremark added Zepbound back as an additional preferred option on October 1, 2026, so check your plan before switching.
• Wegovy is the first-line alternative for displaced patients — Caremark-preferred, same chronic weight management indication, with a labeled CV benefit Zepbound lacks — but it is a different molecule with a meaningfully smaller mean weight-loss effect across the published trial record. Wegovy is NOT equivalent to Zepbound.
• Mounjaro is the same molecule but T2D-only indicated; not a practical alternative without diabetes.
• Foundayo (oral GLP-1, -11.1% at 17.2 mg labeled max, $149/month) is the cheapest FDA-approved brand-name option and one of two oral choices (with the Wegovy pill); expect roughly half the weight loss vs Zepbound 15 mg.
• Compounded tirzepatide ($200-$300/month) is regulatory gray-zone after the October 2024 enforcement-discretion end; not a recommended path.
• Brand Zepbound via LillyDirect Self Pay ($299-$449) or Sam's Club Plus ($299-$699 KwikPen) is sometimes cheaper than alternatives at the lower doses.
• For OSA-indicated patients: Zepbound is currently the ONLY FDA-approved option. Wegovy, Foundayo, Saxenda, Mounjaro, Qsymia, and Contrave are not labeled for OSA. Pursue the insurance appeal.

The choice between Zepbound, Wegovy, Foundayo, Mounjaro, and compounded tirzepatide should be made with a prescribing clinician who knows your medical history. Pricing is current as of May 2026 and is updated as the manufacturer programs change. Effect-size data is from the cited registration trials and reflects population means; individual outcomes vary substantially. Cross-trial comparisons are indirect; only SURMOUNT-5 (tirzepatide vs semaglutide) and SURPASS-2 (T2D context) are direct head-to-heads.

Further reading

• Top GLP-1 insurance-coverage questions on Reddit, answered
• Top tirzepatide weight-loss studies (curated PubMed reading list)
• GLP-1 contraindications cheat sheet